Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective

Vector-Borne and Zoonotic Diseases

Volumn 15, Issue 6, 2015, Pages 385-396

  McVey, D Scott ^a   MacLachlan, N James ^b  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arbovirus; Bluetongue; Epizootic hemorrhagic disease; Immunity; Orbivirus; Vaccines

Indexed keywords

AUTOVACCINE; BLUETONGUE VACCINE; INACTIVATED VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MODIFIED LIVE VIRUS VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

BLUETONGUE; BLUETONGUE ORBIVIRUS; CONVALESCENCE; DRUG EFFICACY; DRUG SAFETY; EPIZOOTIC HAEMATOPOIETIC NECROSIS VIRUS; EPIZOOTIC HEMORRHAGIC DISEASE; HUMORAL IMMUNITY; LIVESTOCK; NONHUMAN; NORTH AMERICAN; PRIORITY JOURNAL; REVIEW; RUMINANT; UNITED STATES; VACCINATION; VIREMIA; VIRUS IMMUNITY; ANIMAL; IMMUNOLOGY; NORTH AMERICA; ORBIVIRUS; REOVIRIDAE INFECTIONS; SHEEP; VETERINARY;

ARBOVIRUS; CAPRA HIRCUS; HEXAPODA; ODOCOILEUS VIRGINIANUS; ORBIVIRUS; OVIS ARIES; UNGULATA;

ANIMALS; BLUETONGUE; BLUETONGUE VIRUS; HEMORRHAGIC DISEASE VIRUS, EPIZOOTIC; LIVESTOCK; NORTH AMERICA; REOVIRIDAE INFECTIONS; RUMINANTS; SHEEP; VIRAL VACCINES;

EID: 84931838822     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2014.1698     Document Type: Review

References (136)

1. Alexander RA, Haig DA. The use of egg-attenuated bluetongue virus in the production of a polyvalent vaccine for sheep: a propagation of the virus in sheep. Onderstepoort J Vet Res 1951;25:3-15.
2. Anderson J, Hagglund S, Breard E, Comtet L and others. Evaluation of the immunogenicity of an experimental DIVA subunit vaccine against Bluetongue virus serotype 8 in cattle. Clin Vaccine Immunol 2013;8:1115-1122.
3. Barber TL. Temporal appearance, geographic distribution, and species of origin of bluetongue virus serotypes in the United States. Am J Vet Res 1979; 40:1654-1656.
4. Bartram DJ, Heasman L, Batten CA, Oura CA and others. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines. Vet J 2011;188:193-196.
5. Batten CA, Edwards L, Oura CA. Evaluation of the humoral immune responses in adult cattle and sheep, 4 and 2.5 years post-vaccination with a bluetongue serotype 8 inactivated vaccine. Vaccine 2013;31:3783-3785.
6. Batten CA, Maan S, Shaw AE, Maan NS, Mertens PP. A European field strain of bluetongue virus derived from two parental vaccine strains by genome segment reassortment. Virus Res 2008;137:56-63.
7. Bonneau KR, DeMaula CD, Mullens BA, MacLachlan NJ. Duration of viraemia infectious to Culicoides sonorensis in bluetongue virus-infected cattle and sheep. Vet Microbiol 2002; 88:115-125.
8. Boone JD, Balasuriya UB, Karaca K, Audonnet JC and others. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 2007;25:672-678.
9. Calistri P, Giovannini A, Conte A, Nannini D and others. Bluetongue in Italy: Part I. Vet Ital 2004;40:243-251.
10. Calistri P, Giovannini A, Savini G, Bonfanti L and others. Antibody response in cattle vaccinated against bluetongue serotype 8 in Italy. Transbound Emerg Dis 2010;57:180-184.
11. Calvo-Pinilla E, Castillo-Olivares J, Jabbar T, Ortego J, de la Poza F, Marín-López A. Recombinant vaccines against bluetongue virus. Virus Res 2014; 182:78-86
12. Calvo-Pinilla E, Navasa N, Anguita J, Ortego J. Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus. PLoS One 2012;7:e34735.
13. Calvo-Pinilla E, Rodriguez-Calvo T, Sevilla N, Ortego J. Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection. Vaccine 2009;28:437-445.
14. Campbell CH, Barber TL, Knudsen RC, Swaney LM. Immune response of mice and sheep to bluetongue virus inactivated by gamma irradiation. Prog Clin Biol Res 1985; 178:639-647.
15. Campbell CH, Breese SS, Jr., McKercher PD. Antigenic and morphologic comparisons of Ibaraki and bluetongue viruses. Can J Microbiol 1975;21:2098-2102.
16. th International Symposium of the World Association of Veterinary Laboratory Diagnosticians. 2005. Montevidio, Uruguay.
17. Celma CC, Boyce M, van Rijn PA, Eschbaumer M and others. Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep. J Virol 2013;87:9856-9864.
18. Chauveau E, Doceul V, Lara E, Adam M and others. Sensing and control of bluetongue virus infection in epithelial cells via RIG-I and MDA5 helicases. J Virol 2012;86:11789-11799.
19. Darpel KE, Monaghan P, Simpson J, Anthony SJ and others. Involvement of the skin during bluetongue virus infection and replication in the ruminant host. Vet Res 2012;43:40.
20. DeMaula CD, Bonneau KR, MacLachlan NJ. Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. Virus Res 2000;67:59-66.
21. Di Emidio B, Nicolussi P, Patta C, Ronchi GF and others. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet Ital 2004;40:640-644.
22. Dungu B, Gerdes T, Smit T. The use of vaccination in the control of bluetongue in southern Africa. Vet Ital 2004a;40:616-622.
23. Dungu B, Potgieter C, Von Teichman B, Smit T. Vaccination in the control of bluetongue in endemic regions: the South African experience. Dev Biol (Basel) 2004b;119:463-472.
24. Erasmus BJ. The control of bluetongue in an enzootic situation. Aust Vet J 1975;51:209-10.
25. Eschbaumer M, Eschweiler J, Hoffmann B. Long-term persistence of neutralising antibodies against bluetongue virus serotype 8 in naturally infected cattle. Vaccine 2012;30:7142-7143.
26. Eschbaumer M, Hoffmann B, Konig P, Teifke JP and others. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep. Vaccine 2009;27:4169-4175.
27. Ferrari G, De Liberato C, Scavia G, Lorenzetti R and others. Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy. Prev Vet Med 2005;68:103-113.
28. Flanagan M, Johnson SJ. The effects of vaccination of Merino ewes with an attenuated Australian bluetongue virus serotype 23 at different stages of gestation. Aust Vet J 1995;72:455-457.
29. Gerbier G, Hendrikx P, Roger F, Zientara S, Biteau-Coroller F, Grillet C, Baldet T, Albina E. Bluetongue control using vaccines: experience of the Mediterranean islands. Vet Ital. 2004; 40:611-615.
30. Gerbier G, Biteau-Coroller F, Grillet C, Parodi J, Zientara S, Baldet T, Guis H, Roger F. Description of the outbreak of bluetongue in Corsica in 2003, and lessons for surveillance. Vet Rec 2008;162:173-176.
31. Gethmann J, Huttner K, Heyne H, Probst C and others. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 2009;27:4118-4126.
32. Gibbs EP, Greiner EC. The epidemiology of bluetongue. Comp Immunol Microbiol Infect Dis 1994;17:207-220.
33. Gibbs EP, Greiner EC, Taylor WP, Barber TL, House JA, Pearson JE. Isolation of bluetongue virus serotype 2 from cattle in Florida: serotype of bluetongue virus hitherto unrecognized in the Western Hemisphere. Am J Vet Res 1983;44:2226-2228.
34. Giovannini A, Calistri P, Conte A, Savini L and others. Bluetongue virus surveillance in a newly infected area. Vet Ital 2004a;40:188-197.
35. Giovannini A, Calistri P, Nannini D, Paladini C and others. Bluetongue in Italy: Part II. Vet Ital 2004b;40:252-259.
36. Giovannini A, Conte A, Calistri P, Di Francesco C and others. Risk analysis on the introduction into free territories of vaccinated animals from restricted zones. Vet Ital 2004c;40:697-702.
37. Gomez-Tejedor C. Brief overview of the bluetongue situation in Mediterranean Europe, 1998-2004. Vet Ital 2004;40:57-60.
38. Guis H, Caminade C, Calvete C, Morse AP and others. Modelling the effects of past and future climate on the risk of bluetongue emergence in Europe. J R Soc Interface 2012;9:339-350.
39. Hamers C, Galleau S, Chery R, Blanchet M and others. Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle. Vet Rec 2009a;165:369-373.
40. Hamers C, Rehbein S, Hudelet P, Blanchet M and others. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep. Vaccine 2009b;27:2789-2793.
41. Hammoumi S, Breard E, Sailleau C, Russo P and others. Studies on the safety and immunogenicity of the South African bluetongue virus serotype 2 monovalent vaccine: specific detection of the vaccine strain genome by RT-PCR. J Vet Med B Infect Dis Vet Public Health 2003;50:316-321.
42. Heidner HW, Rossitto PV, MacLachlan NJ. Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants. Virology 1990;176:658-661.
43. Hulten C, Frossling J, Chenais E, Sternberg Lewerin S. Seroprevalence after Vaccination of Cattle and Sheep against Bluetongue Virus (BTV) Serotype 8 in Sweden. Transbound Emerg Dis 2012;60:438-447.
44. Hund A, Gollnick N, Sauter-Louis C, Neubauer-Juric A and others. A two year BTV-8 vaccination follow up: Molecular diagnostics and assessment of humoral and cellular immune reactions. Vet Microbiol 2012:154:247-256.
45. Inaba U. Ibaraki disease and its relationship to bluetongue. Aust Vet J 1975;51:178-185.
46. Inaba Y, Tanaka Y, Ishii S, Morimoto T and others. Ibaraki virus, an agent of epizootic disease of cattle resembling bluetongue. IV. Physicochemical and serological properties of the virus. Jpn J Microbiol 1970;14:351-360.
47. Jabbar TK, Calvo-Pinilla E, Mateos F, Gubbins S and others. Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2. PLoS One 2013;8:e60574.
48. Jimenez-Clavero MA, Aguero M, San Miguel E, Mayoral T and others. High throughput detection of bluetongue virus by a new real-time fluorogenic reverse transcription-polymerase chain reaction: application on clinical samples from current Mediterranean outbreaks. J Vet Diagn Invest 2006;18:7-17.
49. Johnson D J. Identification of new United States bluetongue types. Proc Ann Meeting US Anim Hlth Assoc 2007; 111:209-210.
50. Kitano Y. Ibaraki disease in cattle. In: Coetzer JA, Tustin RC, eds. Infectious Disease of Livestock. Cape Town: Oxford University Press; 2004:1221-1226.
51. Leemans J, Hamers C, Chery R, Bibard A and others. Interference of colostral antibodies with response to a Bluetongue serotype 8 inactivated vaccine in lambs born from hyperimmune ewes. Vaccine 2013;31:1975-1980.
52. Leemans J, Raes M, Saegerman C, Sustronck B and others. Effect of an inactivated bluetongue serotype 8 vaccine on semen quality in rams. Vet J 2012;193:567-569.
53. Lobato ZI, Coupar BE, Gray CP, Lunt R and others. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet Immunol Immunopathol 1997;59:293-309.
54. Lourenco S, Roy P. In vitro reconstitution of Bluetongue virus infectious cores. Proc Natl Acad Sci U S A 2011;108:13746-13751.
55. Ma G, Eschbaumer M, Said A, Hoffmann B and others. An equine herpesvirus type 1 (EHV-1) expressing VP2 and VP5 of serotype 8 bluetongue virus (BTV-8) induces protection in a murine infection model. PLoS One 2012;7:e34425.
56. Maclachlan NJ. Bluetongue: History, global epidemiology, and pathogenesis. Prev Vet Med 2011;102:107-111.
57. Maclachlan NJ, Conley AJ, Kennedy PC. Bluetongue and equine viral arteritis viruses as models of virus-induced fetal injury and abortion. Anim Reprod Sci 2000; 60/61:643-651.
58. Maclachlan NJ, Drew CP, Darpel KE, Worwa G. The pathology and pathogenesis of bluetongue. J Comp Pathol 2009;141:1-16.
59. Maclachlan NJ, Mayo CE. Potential strategies for control of bluetongue, a globally emerging, Culicoides-transmitted viral disease of ruminant livestock and wildlife. Antiviral Res 2013a; 99:79-90.
60. MacLachlan NJ, Osburn BI. Bluetongue virus-induced hydranencephaly in cattle. Vet Pathol 1983;20:563-573.
61. MacLachlan NJ, Osburn BI. Congenital bluetongue virus infection. Prog Clin Biol Res 1988;281:33-47.
62. Maclachlan NJ, Osburn BI. Induced brain lesions in calves infected with bluetongue virus. Vet Rec 2008; 162:490-491.
63. MacLachlan NJ, Osburn BI, Ghalib HW, Stott JL. Bluetongue virus-induced encephalopathy in fetal cattle. Vet Pathol 1985;22:415-417.
64. MacLachlan NJ, Rossitto PV, Heidner HW, Iezzi LG and others. Variation amongst the neutralizing epitopes of bluetongue viruses isolated in the United States in 1979-1981. Vet Microbiol 1992;31:303-316.
65. Maclachlan NJ, Wilson WC, Crossley BM, Mayo CE and others. Novel serotype of bluetongue virus, western North America. Emerg Infect Dis 2013b;19:665-666.
66. MAPA. Report of the efficacy test performed in Spain with different commercially available vaccine against BTV4 in cattle and sheep. MAPA Report2006.
67. McKercher DG, McGowan B Jr, Cabasso VJ, Roberts GI, Saito JK. Studies on bluetongue. III. The development of a modified live virus vaccine employing American strains of bluetongue virus. Am J Vet Res 1957; 18:310-316.
68. McKercher DG, McGowan B, Howarth JA, Saito JK. A preliminary report on the isolation and identification of the bluetongue virus from sheep in California. J Am Vet Med Assoc 1953; 122:300-301.
69. Mellor PS, Carpenter S, Harrup L, Baylis M and others. Bluetongue in Europe and the Mediterranean Basin: history of occurrence prior to 2006. Prev Vet Med 2008;87:4-20.
70. Mellor PS, Leake CJ. Climatic and geographic influences on arboviral infections and vectors. Rev Sci Tech 2000;19:41-54.
71. Mertens PP, Diprose J, Maan S, Singh KP and others. Bluetongue virus replication, molecular and structural biology. Vet Ital 2004;40:426-437.
72. Monaco F, Bonfini B, Zaghini M, Antonucci D and others. Vaccination of cattle using monovalent modified-live vaccine against bluetongue virus serotype 2: innocuity, immunogenicity and effect on pregnancy. Vet Ital 2004a;40:671-675.
73. Monaco F, Camma C, Serini S, Savini G. Differentiation between field and vaccine strain of bluetongue virus serotype 16. Vet Microbiol 2006;116:45-52.
74. Monaco F, De Luca N, Morelli D, Pisciella M and others. Field vaccination of cattle using a bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9: effect on milk production. Vet Ital 2004b;40:661-663.
75. Monaco F, De Luca N, Spina P, Morelli D and others. Virological and serological response of cattle following field vaccination with bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9. Vet Ital 2004c;40:657-660.
76. Moulin V, Noordegraaf CV, Makoschey B, van der Sluijs M and others. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine. Vaccine 2012;30:2228-2235.
77. Murphy MD, Howerth EW, MacLachlan NJ, Stallknecht DE. Genetic variation among epizootic hemorrhagic disease viruses in the southeastern United States: 1978-2001. Infect Genet Evol 2005;5:157-165.
78. Noad R, Roy P. Bluetongue vaccines. Vaccine 2009; 27 Suppl 4:D86-89.
79. st Edition, Office International des Epizooties, Paris.
80. Osburn BI, de Mattos CA, de Mattos CC, MacLachlan NJ. Bluetongue disease and the molecular epidemiology of viruses from the western United States. Comp Immunol Microbiol Infect Dis 1996; 19:181-190.
81. Oura CA, Edwards L, Batten CA. Evaluation of the humoral immune response in adult dairy cattle three years after vaccination with a bluetongue serotype 8 inactivated vaccine. Vaccine 2012;30:112-115.
82. Oura CA, Wood JL, Floyd T, Sanders AJ and others. Colostral antibody protection and interference with immunity in lambs born from sheep vaccinated with an inactivated Bluetongue serotype 8 vaccine. Vaccine 2010;28:2749-2753.
83. Oura CA, Wood JL, Sanders AJ, Bin-Tarif A and others. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep. Vaccine 2009;27:7326-7330.
84. Parker J, Herniman KA, Gibbs EP, Sellers RF. An experimental inactivated vaccine against bluetongue. Vet Rec 1975; 96: 284-287.
85. Patta C, Giovannini A, Rolesu S, Nannini D and others. Bluetongue vaccination in Europe: the Italian experience. Vet Ital 2004;40:601-610.
86. Perez de Diego AC, Athmaram TN, Stewart M, Rodriguez-Sanchez B and others. Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep. PLoS One 2011;6:e26666.
87. Perez de Diego AC, Sanchez-Cordon PJ, de las Heras AI, Sanchez-Vizcaino JM. Characterization of the immune response induced by a commercially available inactivated bluetongue virus serotype 1 vaccine in sheep. ScientificWorldJournal 2012;2012:147158.
88. Perrin A, Albina E, Breard E, Sailleau C and others. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 2007;25:6774-6783.
89. Probst C, Gethmann JM, Horeth-Bontgen D, Cussler K and others. Lack of evidence for claims of farmers in southeastern Germany regarding adverse reactions ascribed to BTV-8 vaccines. Berl Munch Tierarztl Wochenschr 2011;124:282-287.
90. Purse BV, Brown HE, Harrup L, Mertens PP and others. Invasion of bluetongue and other orbivirus infections into Europe: the role of biological and climatic processes. Rev Sci Tech 2008;27:427-442.
91. Purse BV, Mellor PS, Rogers DJ, Samuel AR and others. Climate change and the recent emergence of bluetongue in Europe. Nat Rev Microbiol 2005;3:171-181.
92. Rodriguez-Sanchez B, Iglesias-Martin I, Martinez-Aviles M, Sanchez-Vizcaino JM. Orbiviruses in the Mediterranean basin: updated epidemiological situation of Bluetongue and new methods for the detection of BTV serotype 4. Transbound Emerg Dis 2008;55:205-214.
93. Rossitto PV, MacLachlan NJ. Neutralizing epitopes of the serotypes of bluetongue virus present in the United States. J Gen Virol 1992;73 (Pt 8):1947-1952.
94. Ruscanu S, Jouneau L, Urien C, Bourge M and others. Dendritic Cell Subtypes from Lymph Nodes and Blood Show Contrasted Gene Expression Programs upon Bluetongue Virus Infection. Journal of Virology 2013;87:9333-9343.
95. Ruscanu S, Pascale F, Bourge M, Hemati B and others. The double-stranded RNA bluetongue virus induces type I interferon in plasmacytoid dendritic cells via a MYD88-dependent TLR7/8-independent signaling pathway. J Virol 2012;86:5817-5828.
96. Saegerman C, Berkvens D, Mellor PS. Bluetongue epidemiology in the European Union. Emerg Infect Dis 2008;14:539-544.
97. Savini G, Afonso A, Mellor P, Aradaib I and others. Epizootic haemorrhagic disease. Res Vet Sci 2011; 91:1-17.
98. Savini G, Conte A, Di Gennaro A, Leone A and others. Virological and serological responses in cattle following vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4, 9 and 16. Ninth International Symposium on ds-RNA Viruses. 2006a. Cape Town, South Africa.
99. th World Buiatrics Congress. Nice, France.
100. Savini G, Lorusso A, Paladini C, Migliaccio P and others. Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: a retrospective analysis in Italy. Transbound Emerg Dis 2014; 61:69-74.
101. Savini G, MacLachlan NJ, Sanchez-Vizcaino JM, Zientara S. Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 2008;31:101-120.
102. Savini G, Monaco F, Calistri P, Panichi G and others. Neutralising antibody response in cattle after vaccination with monovalent modified-live vaccine against bluetongue virus serotype 2. Vet Ital 2004a;40:668-670.
103. Savini G, Monaco F, Citarella R, Calzetta G and others. Monovalent modified-live vaccine against bluetongue virus serotype 2: immunity studies in cows. Vet Ital 2004b;40:664-667.
104. Schultz G, Delay PD. Losses in newborn lambs associated with bluetongue vaccination of pregnancy ewes. J Am Vet Med Assoc 1955;127:224-226.
105. Stevens DR, Stott J, Osburn BI, Giles R and others. Potency and efficacy of inactivated bluetongue virus vaccines. Prog Clin Biol Res 1985; 178:649-652.
106. Stewart M, Dovas CI, Chatzinasiou E, Athmaram TN and others. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection. Vaccine 2012;30:2131-2139.
107. Stewart M, Dubois E, Sailleau C, Breard E and others. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen. Vaccine 2013;31:553-558.
108. Stott JL, Barber TL, Osburn BI. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res 1985;46:1043-1049.
109. Stott JL, Blanchard-Channell M, Scibienski RJ, Stott ML. Interaction of bluetongue virus with bovine lymphocytes. J Gen Virol 1990;71 (Pt 2):363-368.
110. Stott JL, Osbourn BI, Barber TL. The current status of research on an experimental inactivated bluetongue virus vaccine. Proc Annu Meet US Anim Health Assoc 1979;83:55-62.
111. Szmaragd C, Gunn GJ, Gubbins S. Assessing the consequences of an incursion of a vector-borne disease. II. Spread of bluetongue in Scotland and impact of vaccination. Epidemics 2010a;2:139-147.
112. Szmaragd C, Wilson A, Carpenter S, Mertens PP and others. Mortality and case fatality during the recurrence of BTV-8 in northern Europe in 2007. Vet Rec 2007;161:571-572.
113. Szmaragd C, Wilson AJ, Carpenter S, Wood JL and others. The spread of bluetongue virus serotype 8 in Great Britain and its control by vaccination. PLoS One 2010b;5:e9353.
114. Tabachnick WJ. Culicoides and the global epidemiology of bluetongue virus infection. Vet Ital 2004;40:144-150.
115. Tabachnick WJ. Challenges in predicting climate and environmental effects on vector-borne disease episystems in a changing world. J Exp Biol 2010;213:946-954.
116. Theiler A. The inoculation of sheep and the results in practice. Veterinary Journal 1908;64:600-607.
117. Thomas FC. Plaque neutralization cross reactivity of post infection bovine sera amongst bluetongue virus serotypes. Prog Clin Biol Res 1985;178:511-12.
118. Thuenemann EC, Meyers AE, Verwey J, Rybicki EP and others. A method for rapid production of heteromultimeric protein complexes in plants: assembly of protective bluetongue virus-like particles. Plant Biotechnol J 2013;11:839-846.
119. Toussaint JF, Vandenbussche F, Mast J, De Meester L and others. Bluetongue in northern Europe. Vet Rec 2006;159:327.
120. van der Sluijs MT, Schroer-Joosten DP, Fid-Fourkour A, Smit M and others. Transplacental transmission of BTV-8 in sheep: BTV viraemia, antibody responses and vaccine efficacy in lambs infected in utero. Vaccine 2013;31:3726-3731.
121. van der Sluijs MT, Schroer-Joosten DP, Fid-Fourkour A, Vrijenhoek MP and others. Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers. Vaccine 2012;30:647-655.
122. Venter GJ, Gerdes GH, Mellor PS, Paweska JT. Transmission potential of South African Culicoides species for live-attenuated bluetongue virus. Vet Ital 2004;40:198-202.
123. Veronesi E, Darpel KE, Hamblin C, Carpenter S and others. Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4. Vaccine 2010;28:1397-1403.
124. Veronesi E, Hamblin C, Mellor PS. Live attenuated bluetongue vaccine viruses in Dorset Poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 2005; 23:5509-5516.
125. Verwoerd DW. History of Orbivirus research in South Africa. J S Afr Vet Assoc 2012;83:E1-6.
126. Verwoerd DW, Erasmus BJ. Bluetongue. In: JAW C, RC T, eds. Infectious Diseases of Livestock. Cape Town: Oxford University Press; 2004:1201-1220.
127. Vitour D, Guillotin J, Sailleau C, Viarouge C and others. Colostral antibody induced interference of inactivated bluetongue serotype-8 vaccines in calves. Vet Res 2011;42:18.
128. Wackerlin R, Eschbaumer M, Konig P, Hoffmann B and others. Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle. Vaccine 2010;28:4348-4355.
129. Wade-Evans AM, Romero CH, Mellor P, Takamatsu H and others. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 1996;220:227-231.
130. White JR, Eaton BT. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup. J Gen Virol 1990;71 (Pt 6):1325-1332.
131. Wilson A, Mellor P. Bluetongue in Europe: vectors, epidemiology and climate change. Parasitol Res 2008;103 Suppl 1:S69-77.
132. Wilson AJ, Mellor PS. Bluetongue in Europe: past, present and future. Philos Trans R Soc Lond B Biol Sci 2009;364:2669-2681.
133. Zanella G, Breard E, Sailleau C, Zientara S and others. A One-year Follow-up of Antibody Response in Cattle and Sheep after Vaccination with Serotype 8- and Serotype 1-inactivated Vaccines. Transbound Emerg Dis 2013a;61:473-476.
134. Zanella G, Martinelle L, Guyot H, Mauroy A and others. Clinical pattern characterization of cattle naturally infected by BTV-8. Transbound Emerg Dis 2013b;60:231-237.
135. Zientara S, MacLachlan NJ, Calistri P, Sanchez-Vizcaino JM, Savini G. Bluetongue vaccination in Europe.Expert Rev Vaccines 2010; 9:989-991.
136. Zientara S, Sanchez-Vizcaino JM. Control of bluetongue in Europe. Vet Microbiol 2013;165:33-37.